Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
24 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to...
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
17 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing...
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
07 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently...
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
03 févr. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst
28 janv. 2022 13h46 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
10 janv. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
04 janv. 2022 07h30 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
06 déc. 2021 07h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 16h15 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h14 HE
|
Catalyst Pharmaceuticals, Inc.
Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S....